Effects of febuxostat in different doses on uric acid, inflammatory factors of serum and knee articular cavity, endothelin-1, and oxidative stress in patients with a gout-a comparative study.

OBJECTIVE: The present comparative study aimed to investigate the effects of different doses of febuxostat on uric acid, inflammatory factors of serum, knee articular cavity, endothelin-1, and oxidative stress in patients with gout. METHODS: 80 cases with hyperuricemia admitted to our hospital (January 2018- March 2020) were randomly distributed into two groups. The control group was administered 40 mg of febuxostat tablets daily., whereas the treatment group was administered febuxostat tablets 80 mg daily. Data were collected from two groups of patients, including uric acid level, TNF-α levels of serum and knee articular cavity, vascular endothelial function, and complications 1 month after the intervention. RESULTS: After data intervention, the levels of uric acid, TNF-α levels of serum, and knee articular cavity, NO, and SOD were significantly different between the treatment group and the control group (each p< 0.05). There were no significant differences in abdominal pain and diarrhea, liver damage, kidney damage, acute gout, and pruritus between the two groups (p >0.05). The duration of activity disorder, pain duration, and swelling in the treatment group were significantly shorter than those in the control group (p< 0.05). The uric acid level was positively correlated with serum TNF-α level (p < 0.05), and negatively correlated with NO and SOD levels (p < 0.05). CONCLUSION: For hyperuricemia-induced gout patients, taking a large dose of 80 mg febuxostat daily can significantly reduce the uric acid level and inflammatory response, improve vascular endothelial function, enhance antioxidant ability, and improve the clinical symptoms of patients without increasing the adverse reactions to medication.